Increased Pretransplant Frequency of CD28⁺ CD4⁺ T_EM Predicts Belatacept-Resistant Rejection in Human Renal Transplant Recipients.

ABSTRACT: While most human T cells express the CD28 costimulatory molecule constitutively, it is well known that age, inflammation, and viral infection can drive the generation of CD28^null T cells. In vitro studies have demonstrated that CD28^null cell effector function is not impacted by the presence of the CD28 costimulation blocker belatacept. As such, a prevailing hypothesis suggests that CD28^null cells may precipitate costimulation blockade-resistant rejection. However, CD28⁺ cells possess more proliferative and multifunctional capacity, factors that may increase their ability to successfully mediate rejection. Here, we performed a retrospective immunophenotypic analysis of adult renal transplant recipients who experienced acute rejection on belatacept

SUBMITTER: Cortes-Cerisuelo M 

PROVIDER: S-EPMC5599135 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature